TABLE 4.
Summary of PD-L1 Expression and Correlation With Objective Responses in the RCC and Melanoma Trials
| Tumor Type |
Agent | No. With Tissue |
Definition of PD-L1+ * |
% PD-L1+ (n) | ORR PD-L1+ (n) |
ORR PD-L1- (n) |
IHC Antibody/ Miscellaneous |
|
|---|---|---|---|---|---|---|---|---|
| Brahmer et al46 | Solid tumors | Nivolumab | 9 | ≥5% | 44% (4/9) | 75% (3/4) | 0% (0/5) | L. Chen† |
| Topalian et al47 | Solid tumors | Nivolumab | 42 (5 RCC, 18 melanoma) | ≥5% | 60% (25/42) | 36% (9/25) | 0% (0/17) | L. Chen† |
| Cho et al58 | RCC | MPDL3280A | 31 | ≥5% | 33% (10/31) | 20% (2/10) | 10% (2/21) | Genentech Ab |
| Hamid et al59 | Melanoma | MPDL3280A | 38 | ≥5% | 39% (15/38) | 27% (4/15) | 20% (3/15) | Genentech Ab |
| Weber et al51 | Melanoma | Nivolumab | 44 | >5% | 27% (12/44) | 67%‡ (8/12) | 19% (6/32) | P = 0.004 |
| >1% | 54% (23/44) | 39% (9/23) | 23% (5/21) | |||||
| Wolchok et al55 | Melanoma | Nivolumab + ipilimumab | 56 | ≥5% | 38% (21/56) | Clone 28-8§ | ||
| Concurrent | 46% (6/13) | 41% (9/22) | P > 0.99, NSS | |||||
| Sequential | 50% (4/8) | 8% (1/13) |
*
PD-L1 testing was generally done on the tumor cells with the exception of MPDL3280A in which case the investigators reported the PD-L1 positivity of the tumor infiltrating immune cells.
†
Murine anti-human B7-H1 (PD-L1) monoclonal antibody clone 5H1.
‡
Statistically significant.
§
Rabbit monoclonal antihuman PD-L1 antibody known as clone 28-8 and Dako’s automated assay.
Ab indicates antibody; IHC, immunohistochemistry; NSS, not statistically significant.